Evidence map›Paper›PMID 25615279›Full record

ArticleBlood cancer journal2015

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

T W Farren, J Giustiniani, M Fanous, F Liu, M G Macey, F Wright, A Prentice, A Nathwani, S G Agrawal

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Measurable residual disease in the treatment of chronic lymphocytic leukemia.Journal of clinical and experimental hematopathology : JCEH · 2020
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

T W Farren1] Department of Haemato-Oncology and Immunophenotyping Section, Barts Health NHS Trust, London, UK [2] Pathology Group, Blizard Institute, Queen Mary University of London, London, UK.
J GiustinianiLaboratoire de Thérapie Cellulaire, Institut Jean Godinot, 1 Avenue du Général Koenig, Reims, France.
M FanousPathology Group, Blizard Institute, Queen Mary University of London, London, UK.
F LiuPathology Group, Blizard Institute, Queen Mary University of London, London, UK.
M G MaceyDepartment of Haemato-Oncology and Immunophenotyping Section, Barts Health NHS Trust, London, UK.
F WrightDepartment of Haematology, The Royal Free Hospital, London, UK.
A PrenticeDepartment of Haematology, The Royal Free Hospital, London, UK.
A NathwaniUCL Cancer Institute, University College London, London, UK.
S G Agrawal1] Department of Haemato-Oncology and Immunophenotyping Section, Barts Health NHS Trust, London, UK [2] Pathology Group, Blizard Institute, Queen Mary University of London, London, UK.
Queen Mary University of London · GBBarts Health NHS Trust · GBUniversity College London · GBCRUK Lung Cancer Centre of Excellence · GBInstitut Jean Godinot · FR

Funding

Department of Health RP-PG-0310-1001
6 · The paper itself

Abstract

In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting. However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated detection of the B cell, tumor-specific antigen CD160 to develop a single-tube, flow cytometry assay (CD160FCA) for CLL MRD to a threshold of 10(-4) to 10(-5). One hundred and eighty-seven patients treated for CLL were enrolled. Utilizing the CD160FCA methodology, there was a high level of comparison between blood and bone marrow (R=0.87, P<0.001). In a validation cohort, CD160FCA and the international standardised approach of the European Research Initiative on CLL group demonstrated high concordance (R=0.91, P<0.01). Patients in complete remission (CR) and CD160FCA negative had longer event-free survival (EFS) (63 vs 16 months, P<0.01) and prolonged time to next treatment (60 vs 15 months, P<0.001) vs MRD positive patients; with a median time to MRD positivity of 36 months. In multivariate analysis, CD160FCA MRD detection was independently predictive of EFS in patients in CR and even predicted EFS in the good-risk cytogenetic subgroup. CD160FCA offers a simple assay for MRD detection in CLL and gives prognostic information across different CLL risk groups.

Indexed as

Antigens, CDPrognosisAdultAgedChlorambucilDisease-Free SurvivalFemaleFlow CytometryGPI-Linked ProteinsHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedNeoplasm, ResidualReceptors, ImmunologicAntigens, CDCD160 protein, humanChlorambucilGPI-Linked ProteinsReceptors, Immunologic

Identifiers

PMID25615279
PMCPMC4314455
OpenAlexW1986976471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.